

# Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma

21 April 2009

---

Hypofractionated stereotactic radiotherapy was well-tolerated and improved symptoms in patients with recurrent low-grade glioma, according to researchers from the Kimmel Cancer Center at Jefferson. The data were presented at the AACR 100th Annual Meeting 2009.

In a subgroup of [patients](#) who also received chemotherapy with their hypofractionated stereotactic radiotherapy (H-SRT) the median survival time was more than three times longer than patients who only received H-SRT alone according to Shannon Fogh, M.D., a resident in [Radiation Oncology](#) at Thomas Jefferson University Hospital.

The study included 22 patients with evidence of glioma recurrence. All patients were given H-SRT as salvage therapy, and nine of the patients also received chemotherapy. The most common regimen was temozolomide (Temodar).

The median survival time from the time of H-SRT was nine months. Eleven of the patients had a response to [treatment](#) at six-week follow-up. In the subset of patients who received chemotherapy, the median survival time from time of H-SRT was 17 months vs. four months for patients who only received H-SRT.

The role of chemotherapy needs to be evaluated further, Dr. Fogh said, since the small number of patients in this study prevented a multivariate analysis that would account for age, performance status and tumor size.

"There really is no standard of care for recurrent [gliomas](#)," Dr. Fogh said. "H-SRT would be an attractive option because it allows a patient to have a shorter course of treatment. In our study, H-SRT was well-tolerated, and all patients were able to complete the full course of treatment."

Source: Thomas Jefferson University ([news](#) : [web](#))

APA citation: Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma (2009, April 21) retrieved 17 May 2021 from <https://medicalxpress.com/news/2009-04-hypofractionated-stereotactic-radiotherapy-beneficial-recurrent.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*